The future of complementary and integrative medicine research - international perspectives

Witt, Claudia M; Barth, Jürgen; Canella, Claudia

DOI: https://doi.org/10.1159/000381512

Posted at the Zurich Open Repository and Archive, University of Zurich
ZORA URL: https://doi.org/10.5167/uzh-116797
Published Version

Originally published at:
DOI: https://doi.org/10.1159/000381512
The Future of Complementary and Integrative Medicine Research – International Perspectives

Claudia M. Witt  Jürgen Barth  Claudia Canella

Institute for Complementary and Integrative Medicine, University Hospital Zurich and University Zurich, Zurich, Switzerland

Currently, there are about 57,500 CAM trials from all over the world registered in the Cochrane Central Register of Controlled Trials and about 690 systematic CAM reviews in the Cochrane Database. Berman presented a few examples of systematic CAM reviews before concluding with future challenges, such as conducting reliable subgroup analyses (e.g., individual patient data meta-analysis or network meta-analysis) and systematic reviews on complex interventions as well as defining what can be considered as scientifically rigorous or relevant to real-world practice of medicine.

Irving Kirsch: ‘Placebo Effects in Complementary and Conventional Medicine’

Irving Kirsch, Professor emeritus of medicine at the University of Connecticut, University of Hull, Plymouth University, and associate director of Placebos Studies and Therapeutic Encounter (PiPS) at the Beth Israel Deaconess Medical Center in Harvard Medical School provided insights into the most recent research on placebo effects in complementary and conventional medicine. He introduced his presentation with the distinction between placebo response, which is the general reaction to a placebo, and the placebo

Background of the Symposium

In January 2014, Claudia Witt became the new director of the Institute for Complementary and Integrative Medicine at the University Hospital Zurich, based at the University of Zurich. December 1, 2014 she gave her public inauguration lecture as Chair of the institute (fig. 1). On the same day, the institute organized an international symposium on ‘The Future of Complementary and Integrative Medicine Research’, which took place at the University Hospital Zurich. The aim of this half-day symposium was to provide interdisciplinary and international perspectives, which have the potential to bring forward future complementary and integrative medicine research. After the opening speeches by the hospital CEO, the vice president of the university, and the dean of the medical school, 7 speakers from 3 countries (UK, USA, and Switzerland; fig. 2), including Claudia Witt, provided insights into new research developments in clinical, placebo, and comparative effectiveness research as well as systems biology. Their presentations can be viewed at www.iki.usz.ch/forschung/seiten/praesentationen.aspx.

Symposium Summary

Brian Berman: ‘20 Years of the Cochrane Complementary Medicine Field – Where Do We Stand?’

Speaking about ‘20 Years of the Cochrane Complementary Medicine Field – Where do we stand?’, Brian Berman, Professor of Family and Community Medicine and Coordinator of the Cochrane CAM field at the University of Maryland, School of Medicine in Baltimore, provided an overview of the history and current state of the Cochrane Complementary Medicine Field [1]. The aim of the Cochrane Collaboration is preparing, maintaining, and disseminating systematic reviews on the effects of health care interventions. The collaboration consists of 31,000 contributors from more than 120 countries, 39 Cochrane centers, 53 collaborative review groups, 10 subfields, 16 method groups, and 1 consumer network. Currently, there are about 57,500 CAM trials from all over the world registered in the Cochrane Central Register of Controlled Trials and about 690 systematic CAM reviews in the Cochrane Database. Berman presented a few examples of systematic CAM reviews before concluding with future challenges, such as conducting reliable subgroup analyses (e.g., individual patient data meta-analysis or network meta-analysis) and systematic reviews on complex interventions as well as defining what can be considered as scientifically rigorous or relevant to real-world practice of medicine.

Fig. 1. Claudia M. Witt, Chair for Complementary and Integrative Medicine at the University of Zurich.
effect, which corresponds with the effect of a placebo compared to usual treatment and to the natural history of a disease. Supported by several examples of meta-analyses [e.g., 2, 3] and his own research [e.g. 4], Kirsch showed that both in complementary and conventional medicine the placebo effect as well as the medical treatment effect depend on the condition and on various characteristics of the treatment, such as the color of the placebo pill, dose, strength of ‘drug’, brand name, price, and therapeutic relationship. To give one example: 4 placebo pills a day resulted in a higher response rate than 1 placebo pill a day [5]. According to Kirsch, it is therefore necessary to examine within-group pre-post changes in both the active treatment and placebo groups as well as report between-group differences in clinical trials and meta-analyses.

Jürgen Barth: ‘Patient-Doctor-Scientist Interaction: Impact on Treatment Outcome’

In his presentation on ‘Patient – Doctor – Scientist Interaction: Impact on Treatment Outcome’, Jürgen Barth, Research Director at the Institute for Complementary and Integrative Medicine, outlined 3 perspectives that might influence the outcomes of integrative medicine in research and practice. Patient expectations toward treatment are an important patient characteristic with an impact on treatment outcomes [6], but they do not necessarily match with the expectations of health professionals [7]. Thus, communication between physicians and patients in practice might also contribute to better health outcomes, especially if patients perceive the communication as helpful [7]. Patient expectations fuelled by health professionals might therefore also influence outcomes in placebo research. The scientist might also contribute to treatment effects by own expectations (i.e. allegiance). The allegiance towards a specific treatment might bias the research results and overestimate treatment effects [8]. Barth concluded that future research should more often use patient expectations as predictor of treatment response, and that better scales are needed for valid assessment. Since good communication might result in improved working alliance, a critical evaluation of the working alliance during the entire treatment seems necessary. Allegiance effects and biases can be lowered by collaborative trials and by disclosure statements of scientists and doctors.

Paul Dieppe: ‘The Evaluation of Health and Wellbeing’ on ‘wellbeing’

Paul Dieppe, Professor for Health and Wellbeing at the Medical School University of Exeter, shed light on “The Evaluation of Health and Wellbeing” on ‘wellbeing’, discussing the definition of the term, the different approaches to access the topic, and assessment methods used in different disciplines. In this context, Dieppe introduced some ideas by the ancient Greeks, contrasting ‘eudaimonia’ (fulfilling your potential to the benefit of everyone in society) and ‘hedonism’ (personal happiness); he pointed out that in today’s culture most discussions on wellbeing concentrated on personal happiness rather than on the benefits of groups or communities. Many different aspects of our cognitions, emotions, and behaviors as well as the environment and circumstances we live in are used as basis to assess wellbeing, and several different disciplines claim to have suitable assessment methods. According to Dieppe, there are 5 different domains entailing wellbeing: mental health, physical health, social circumstances, spiritual wellbeing, and possessions, for which both subjective (self-report) and more objective measures are used. Dieppe’s colleagues Myles-Jay Linton and Antonieta Medina-Lara are reviewing and classifying all the different ways of measuring wellbeing for the benefit of researchers. However, Dieppe recommended that we need to move from a pathological to a salutogenic understanding of health and wellbeing (the generation of health as promoted by Aaron Antonovsky), thereby focusing on manageability, meaningfulness, and comprehensibility [9, 10]. He concluded that the selected method to evaluate wellbeing should correspond with the research approach, and characterized wellbeing as holistic concept entailing body, mind, and spirit.

Jan van der Greef: ‘Bridging Western and Chinese Medicine with Systems Biology’

Jan van der Greef, Professor of Analytical Bioscience at Leiden University and Principal Scientist at TNO, promoted ‘Bridging Western and Chinese Medicine with Systems Biology’, introducing a ‘systems view on life’. He stated that more than 90% of drugs only work in 30–40% of people in today’s health care. As a result, van der Greef suggested a shift from a ‘one-size fits all’ to ‘personalized’ medicine, or, in terms of systems biology, to Western biomarker-guided medicine supported by the phenomenological approach of Chinese Medicine in diagnosis [11–13]. Further, in his opinion it is mandatory to apply comparative effectiveness research in real-world settings. Such an approach implies analyzing complex inter-dependences of the physical, mental, emotional, social, and spiritual aspects in relation to environmental circumstances of every individual concerned. Van der Greef concluded that personalized medicine must change its focus from symptoms, especially in chronic disease to resilience, against the background of social, physical, and emotional challenges.
Claudia Witt: ‘Comparative Effectiveness Research (CER) in Complementary and Integrative Medicine’

With her presentation of ‘Comparative Effectiveness Research (CER) in Complementary and Integrative Medicine’, Claudia Witt, Professor of Medicine and Director of the Institute for Complementary and Integrative Medicine, provided insights into recent developments in a relatively new research field. She focused on randomized trials and outlined that the eligibility criteria of study participants, the flexibility of the interventions, and the type of outcome measures are key criteria to distinguish between randomized controlled trials providing information on the efficacy of a treatment (evidence from ideal study settings) and randomized pragmatic trials providing evidence on the effectiveness of an intervention (evidence from a usual care study setting). Witt showed that acupuncture research has already made unique contributions to comparative effectiveness research (CER) [14] by developing guiding recommendations [15, 16]. The most recent recommendations even try to close the gap between CER and ‘omics’.

Steven Woolf: ‘The Impact of Stakeholder Engagement – Lessons Learned from Health Services and Public Health Research’

Steven Woolf, Professor of Family Medicine and Director of the VCU Center on Society and Health at Virginia Commonwealth University in Richmond, gave a lecture on ‘The Impact of Stakeholder Engagement – Lessons Learned from Health Services and Public Health Research’. He presented 2 research projects involving stakeholder engagement that had been conducted by his institution [17]. He first noted the emergence of an international trend in health research that emphasizes deeper engagement of the ‘affected party.’

In clinical research, this includes an emphasis on shared decision-making and patient-centered outcome research. A hallmark of this approach is a commitment to stakeholder engagement at every stage of a research project. Woolf described in detail the process of patient engagement that was undertaken in a pilot study on how patients approach decisions about cancer screening. A second example involved community engagement, in which residents of a community in the East End of Richmond helped set population health priorities and developed new causal models about the role of social determinants of health.

Woolf concluded that stakeholder engagement means first of all forging a coequal partnership and a transition from research subjects to co-investigators.

Conclusion

There is already a decent amount of clinical research on complementary and integrative medicine. However, the discussion made clear that the bio-psychosocial understanding of and approach to disease in complementary and integrative medicine goes along with a large amount of complexity that has to be considered when designing future trials. Recent research on placebo as well as new approaches, such as systems biology and CER, could be helpful to guide future research.

Acknowledgment

We thank Maren Schoenfeld for organizing the Symposium and Jürg Lendemann for the photos.